The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
New aggregated polls reveal that 55% of respondents believe marijuana is not dangerous, and a…
Every Croptober, growers waste time on folklore instead of physics. We break down the science…
Leafly's 2026 cannabis voter guide for the midterms is the only plan you need to…
Come along on an Emerald Triangle road trip with Lindsay MaHarry to see some of…
This month an Iowa church got what every sacramental-plant congregation dreams about: a path to…
The cannabis industry does not need another study, another tax revenue report, or another state-level…